VTRS240517C10000
- 1.00
- 0.000.00%
Viatris Newsroom
Viatris Inc's Dividend Analysis
Regeneron Wins Temporary Restraining Order Preventing Eylea Generics
8 Out of 12 S&P 500 Healthcare Companies Beat Profit Consensus This Week: Earnings Scorecard
About 70% of S&P 500 Names Beat EPS, While 47% Soar Past Revenue Estimates This Week - Earnings Scorecard
Viatris Inc. (VTRS) Q1 2024 Earnings: Aligns With EPS Projections Amidst Strategic Shifts and ...
Express News | Viatris Inc : UBS Cuts Target Price to $12 From $13
Viatris | 10-Q: Quarterly report
Research Alert: CFRA Keeps Hold Opinion On Shares Of Viatris Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our 12-month target price at $13
Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecast
Thursday, Viatris Inc (NASDAQ:VTRS) reported first-quarter EPS of $0.67, which is in line with the consensus.The company reported sales of $3.66 billion, missing the consensus of $3.69 billion. Total
Earnings Call Summary | Viatris(VTRS.US) Q1 2024 Earnings Conference
The following is a summary of the Viatris Inc. (VTRS) Q1 2024 Earnings Call Transcript:Financial Performance:Viatris reported Q1 revenue of approximately $3.7 billion, adjusted EBITDA of approximately
Stocks Rebound As Rising Jobless Claims Sustain Rate-Cut Hopes, Dollar Falls, Gold Rallies: What's Driving Markets Thursday?
Wall Street is seeing a day of gains as all major indices traded in the green around noon in New York, driven by a surprising uptick in unemployment claims prompting speculation over Federal Reserve i
Express News | Viatris Shares Down 3.8% After Q1 Revenue Misses Estimates
Research Alert: CFRA Maintains Hold Opinion On Shares Of Viatris Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lower our 12-month target by $1 to $1
Viagra Maker Viatris Misses Revenue Estimates on Weak Demand for Older Drugs
Viatris' Q1 Adjusted Earnings, Revenue Decrease; 2024 Outlook Reduced
Viatris (VTRS) reported Q1 adjusted earnings Thursday of $0.67 per diluted share, down from $0.77 a year earlier. Analysts polled by Capital IQ expected $0.67. Total revenue for the quarter ended Marc
Express News | Viatris Expects 2024 Adjusted EPS Of $2.66-$2.81 Versus Prior Guidance Of $2.70-$2.85 And Consensus Of $2.74
Express News | Viatris Expects 2024 Revenues Of $14.98B-$15.48B Versus Consensus Of $15.19B And Prior Guidance Of $15.25B-$15.75B
Viatris Q1 2024 GAAP EPS $0.67, Inline, Sales $3.663B Miss $3.691B Estimate
Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.67 per share which met the analyst consensus estimate. This is a 12.99 percent decrease over earnings of $0.77 per share from the same period la
Viatris Cuts FY24 View To Adj EPS $2.66-Adj EPS $2.81 >VTRS
Viatris Cuts FY24 View To Adj EPS $2.66-Adj EPS $2.81 >VTRS
Express News | Viatris Inc: Reaffirming Its 2024 Financial Guidance